11/29/2024
In a mechanistic analysis of the SUMMIT trial that tested tirzepatide in patients with heart failure with preserved ejection fraction and obesity, treatment with this dual GLP-1 receptor and GIP agonist, as compared to placebo, reduced blood pressure and estimated circulatory volume-pressure overload, reduced systemic inflammation, and mitigated cardiovascular and kidney injury.
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload...